NOTE

Albiducins A and B, salicylaldehyde antibiotics from the ash tree-associated saprotrophic fungus *Hymenoscyphus albidus*

Sandra Halecker^{1,2}, Frank Surup^{1,2}, Halvor Solheim³ and Marc Stadler^{1,2}

The Journal of Antibiotics (2018) 71, 339-341; doi:10.1038/ja.2017.66; published online 7 June 2017

Since the early 1990s, European ash (*Fraxinus excelsior*) has been facing an onslaught of severe dieback in most of its natural distribution area in Europe. The causal agent of this epidemic disease is the invasive ascomycete *Hymenoscyphus fraxineus* (=Hymenoscyphus pseudoalbidus).^{1–3} This fungal pathogen most probably originates from East Asia and has almost replaced the European sister species *Hymenoscyphus albidus*.^{4,5} The latter species, *H. albidus*, is known in Europe since 1851⁶ as a widespread, non-pathogenic decomposer of ash litter and produces numerous white-stalked apothecia on fallen, previous year's rachises of *F. excelsior*.^{5,7} Apparently, *H. albidus* is threatened with local extinction in regions colonized by *H. fraxineus* due to competitive exclusion from its ecological niche (fallen petioles of *F. excelsior*).⁴

Over the past years, *H. fraxineus* has been studied intensively for virulence factors ultimately responsible for the pathogenicity. The role of previously described secondary metabolites, like the tetramic acid antibiotic hymenosetin,⁸ during infection and necrosis formation has yet to be defined. Actually, the only known phytotoxins of *H. fraxineus*, viridiol and 3,4-dimethylpentan-4-olide, are, however, also produced by the non-pathogenic *H. albidus*.^{9,10}

In the current study, we report the isolation and structure elucidation of two new polyketides, albiducins A and B (1 and 2, Figure 1), from liquid culture extracts of *H. albidus*. Further, these small salicylaldehyde derivatives were evaluated for cytotoxic and antimicrobial activities (Table 1).

The examined strain *H. albidus* 2009-111/1/4 was isolated from apothecia collected in 2009 in Bergen, Norway outside *H. fraxineus*-infected areas¹¹ and unambiguously determined by morphological characterization and sequencing of its ITS rDNA region (details see Supplementary Information). A 50 l scale fermentation of *H. albidus* 2009-111/1/4 was carried out for 20 days at 23 °C in ZM/2 medium. This medium was chosen because previous investigations had revealed its optimal composition for secondary metabolite production of *H. fraxineus.*⁸ After cultivation had been stopped, the biomass was separated by centrifugation and extracted with acetone. The resulting mycelial extract was fractionated using normal-phase and reversed-phase column chromatography, yielding the two new bioactive compounds 1 and 2 (details see Supplementary Information).

Albiducin A (1) was isolated as yellow oil. Its molecular formula C16H20O3 was determined by HRESIMS, indicative of seven units of unsaturation. The UV/Vis spectrum with absorption maxima of 226, 262, 298 and 398 nm indicated an extensive conjugated π system. The ¹H and ¹H,¹³C HSQC spectra showed signals of an aldehyde, six aromatic/olefinic methines, four methylenes along one methyl group. In addition, the ¹³C spectrum revealed the presence of four additional sp² hybridized quaternary carbons; two of which were bound to oxygen as indicated by their deep field chemical shifts. The nona-1,3-dienyl side chain was deduced from ¹H,¹H COSY and TOCSY correlations between protons H-8 to H₃-16 and confirmed by a multitude of intraresidue 1H,13C HMBC correlations (Supplementary Figure S1). HMBC correlations of H-8 to C-2/C-6, H-6 to C-2/C-4/C-8, H-5 to C-3/C-7 and H-1 to C-2/C-3/C-4/C-7 revealed the backbone of 1 (Supplementary Figure S1). Finishing the structure elucidation, the all-*trans*-geometry of the $\Delta^{8,9}$ and $\Delta^{10,11}$ double bonds was assigned based on the vicinal coupling constants ($J_{8,9} = 15.4 \text{ Hz}$; $J_{10,11} = 15.1 \text{ Hz}$). The IUPAC nomenclature of **1** is 2,3-dihydroxy-6-[(1*E*,3*E*)-nona-1,3-dien-1-yl] benzaldehyde.

Albiducin B (2) was analyzed having the molecular formula $C_{16}H_{20}O_2$, which indicated the formal loss of an oxygen atom compared to 1. The proton and carbon spectra of 2 were very similar to those of 1, with the key difference of the appearance of an additional aromatic methine instead of a quaternary carbon. This methine was part of the H-4/H-5/H-6 spin system. Again, J_{H8} , H9 = 15.6 Hz and $J_{H10,H11}$ = 14.9 Hz indicated all-*trans*-geometry of

¹Department of Microbial Drugs, Helmholtz Centre for Infection Research GmbH, Braunschweig, Germany; ²German Centre for Infection Research Association (DZIF), Partner Site Hannover-Braunschweig, Braunschweig, Germany and ³Norwegian Institute of Bioeconomy Research (NIBIO), Ås, Norway

Correspondence: Professor M Stadler, Helmholtz Centre for Infection Research GmbH, Department of Microbial Drugs, Inhoffenstraße 7, 38124 Braunschweig, Germany. E-mail: marc.stadler@helmholtz-hzi.de

Dedicated to Professor KC Nicolaou and his outstanding contributions to complex natural product total synthesis and chemical biology. Received 3 March 2017; revised 6 April 2017; accepted 17 April 2017; published online 7 June 2017



1: R = OH

2: R = H

Figure 1 Structures of albiducins A (1) and B (2).

340

Table 1 Antimicrobial and cytotoxic activities of albiducins A (1) and B (2)

Test organisms	Albiducin A	Albiducin B	Reference
Bacteria	MIC ($\mu g m l^{-1}$)		
Bacillus subtilis DSM 10	16.7	66.7	4.2 ⁰
Micrococcus luteus DSM 1790	33.3	66.7	0.40
Staphylococcus aureus DSM 346	33.3	66.7	0.10
Mycobacterium smegmatis ATCC 700084	n.i.	n.i.	2.1 ^K
Chromobacterium violaceum DSM 30191	n.i.	n.i.	0.4 ⁰
Escherichia coli DSM 1116	n.i.	n.i.	1.7 ⁰
Pseudomonas aeruginosa PA14	n.i.	n.i.	0.5 ^G
Fungi			
Candida albicans DSM 1665	66.7	n.i.	4.2 ^N
Pichia anomala DSM 6766	66.7	n.i.	4.2 ^N
Rhodotorula glutinis DSM 10134	16.7	n.i.	1.0 ^N
Schizosaccharomyces pombe DSM 70572	66.7	n.i.	16.7 ^N
Mucor hiemalis DSM 2656	33.3	n.i.	8.3 ^N
Cell lines	IC ₅₀ (μg ml ⁻¹)		
Mouse fibroblasts L929 (ACC 2)	6.1	25.0	0.0008 ^E
Human cervical carcinoma cell line KB3-1 (ACC 158)	2.7	8.5	—

Abbreviations: $^{E},$ epothilone B; $^{G},$ gentamicin; $^{K},$ kanamycin; $^{N},$ nystatin; n.i., no inhibition; $^{0},$ oxytetracycline.

the $\Delta^{8,9}$ and $\Delta^{10,11}$ double bonds. The IUPAC nomenclature of **2** is 2-hydroxy-6-[(1*E*,3*E*)-nona-1,3-dien-1-yl]benzaldehyde.

Albiducins A (1) and B (2) are members of a group of structurally related small polyketides formally derived from salicylaldehyde (Supplementary Figure S2). Despite their relative simplicity, these small molecules have been found to possess a variety of interesting bioactivities. Their closest relative aurocitrin was isolated from Hypocrea citrina (currently valid name Trichoderma citrinum) and showed strong antibiotic activity against Staphylococcus aureus.12 Furthermore, aurocitrin and its derivatives exhibited moderate antiplasmodial activities and cytotoxicity against three cancer cell lines.¹³ Pyriculariol, produced by the rice blast fungus Pyricularia oryzae, was found to be phytotoxic due to dark necrotic spots caused on rice leaves and growth inhibition of rice seedlings.14 2,4-dihydroxy-6-((1E,3E)-penta-1,3-dien-1-yl)benzaldehyde from the endophytic fungus Periconia atropurpurea was able to induce slight increase in cell proliferation of HeLa and CHO cell lines and showed potent antifungal activity.¹⁵ Another similar compound family, auroglaucin and its derivatives dihydroauroglaucin, isodihydroauroglaucin, flavoglaucin were isolated from '*Eurotium herbariorum*' (currently valid name *Aspergillus glaucus*) and displayed strong antioxidative activity.¹⁶

In our study, the antimicrobial activities of albiducins A (1) and B (2) were evaluated in a serial dilution assay against a broad panel of bacteria and fungi in a similar manner as previously reported¹⁷ (Table 1, details see Supporting Information). Both compounds exhibited weak inhibitory activity against Gram-positive bacteria, including the pathogen *Staphylococcus aureus*. In addition, 1 displayed slight antifungal activity against all tested fungi. The cytotoxicity of 1 and 2 were assayed *in vitro* against the mouse fibroblast cell line L929 and the human cervical carcinoma cell line KB3-1. Both compounds showed moderate IC_{50} values with stronger effect on human cancer cells. In general, 1 was found to be more active than 2. These results are in accordance with above described activities of previously reported structural related compounds.

Albiducin A (<u>1</u>): Yellow oil; UV (MeOH) λ_{max} (log ε): 226 nm (3.84), 260 nm (3.81), 296 nm (3.68), 398 (3.26); ¹H NMR (700 MHz, DMSO-*d*₆): $\delta_{\rm H}$ 10.41 (s, H-1), 7.18 (d, *J*=15.5 Hz, H-8), 7.03 (d, *J*=8.4 Hz, H-5), 7.00 (d, *J*=8.4 Hz, H-6), 6.66 (dd, *J*=15.5 Hz, 10.4 Hz, H-9), 6.22 (dd, *J*=15.1 Hz, 10.4 Hz, H-10), 5.86 (dt, *J*=15.1 Hz, 7.1 Hz, H-11), 2.12 (q, *J*=7.1 Hz, 7.1 Hz, H₂-12), 1.39 (dt, *J*=14.0 Hz, 7.3 Hz, H₂-13), 1.33—1.25 (m, H₂-14, H₂-15), 0.87 (t, *J*=7.0 Hz H₃-16); ¹³C NMR (175 MHz, DMSO-*d*₆): $\delta_{\rm C}$ 195.3 (CH, C-1), 150.6 (qC, C-3), 145.0 (qC, C-4), 135.7 (CH, C-11), 131.5 (CH, C-9), 131.3 (qC, C-7), 130.8 (CH, C-10), 125.6 (CH, C-8), 121.7 (CH, C-5), 118.2 (qC, C-2), 117.0 (CH, C-6), 32.2 (CH₂, C-12), 30.8 (CH₂, C-14), 28.4 (CH₂, C-13), 21.9 (CH₂, C-15), 13.9 (CH₃, C-16); ESIMS *m*/*z* 261.24 [M+H]⁺, 259.10 [M-H]⁻; HRESIMS *m*/*z* 261.1493 [M+H]⁺ (calcd. for C₁₆H₂₁O₃, 261.1485); R_t=14.7 min.

Albiducin B (<u>2</u>): Yellow oil; UV (MeOH) λ_{max} (log ε): 254 nm (3.58), 288 nm (3.34), 372 (2.94); ¹H NMR (500 MHz, DMSO- d_6): δ_H 11.27 (br s, 3-OH), 10.46 (s, H-1), 7.45 (t, J=8.0 Hz, H-5), 7.30 (d, J=15.6 Hz, H-8), 7.14 (d, J=8.0 Hz, H-6), 6.85 (m, H-4), 6.83 (m, H-9), 6.26 (dd, J=15.1 Hz, 10.4 Hz, H-10), 5.95 (dt, J=15.1 Hz, 7.2 Hz, H-11), 2.14 (m, H₂-12), 1.40 (m, H₂-13), 1.33—1.25 (m, H₂-14, H₂-15), 0.87 (t, J=7.0 Hz, H₃-16); ¹³C NMR (125 MHz, DMSO- d_6): δ_C 194.4 (CH, C-1), 162.0 (qC, C-3), 140.8 (qC, C-7), 137.6 (CH, C-11), 136.1 (CH, C-5), 133.9 (CH, C-9), 130.7 (CH, C-10), 125.9 (CH, C-8), 118.1 (qC, C-2), 117.1 (CH, C-6), 115.6 (CH, C-4), 32.2 (CH₂, C-12), 30.9 (CH₂, C-14), 28.3 (CH₂, C-13), 21.9 (CH₂, C-15), 13.9 (CH₃, C-16); ESIMS *m/z* 245.20 [M+H]⁺, 243.10 [M-H]⁻; HRESIMS *m/z* 245.1535 [M+H]⁺ (calcd. for C₁₆H₂₁O₂, 245.1536); R_t = 16.0 min.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We gratefully acknowledge support from COST Action FP1103. In particular, SH would like to thank the COST Action FP1103 for funding an STSM and Jan Stenlid for hosting her stay at the SLU Uppsala. We want to express our gratitude to Barbara Schulz for the profound advice on this topic. We thank Wera Collisi for conducting the bioassays and Christel Kakoschke for recording NMR spectra. For HRESIMS measurements we are grateful to Cäcilia Bergmann. SH gratefully acknowledges the help of Sara Rodrigo with downstream processing after scale-up fermentation.

- 1 Queloz, V. et al. Cryptic speciation in Hymenoscyphus albidus. For. Pathol. 41, 133-142 (2011).
- 2 Gross, A., Holdenrieder, O., Pautasso, M., Queloz, V. & Sieber, T. N. Hymenoscyphus pseudoalbidus, the causal agent of European ash dieback. *Mol. Plant Pathol.* 15, 5–21 (2014).
- 3 Baral, H. O., Queloz, V. & Hosoya, T. *Hymenoscyphus fraxineus*, the correct scientific name for the fungus causing ash dieback in Europe. *IMA Fungus* 5, 79–80 (2014).
- 4 McKinney, L. V., Thomsen, I. M., Kjær, E. D., Bengtsson, S. B. K. & Nielsen, L. R. Rapid invasion by an aggressive pathogenic fungus (*Hymenoscyphus pseudoalbidus*) replaces a native decomposer (*Hymenoscyphus albidus*): a case of local cryptic extinction? *Fungal Ecol.* 5, 663–669 (2012).
- 5 Baral, H. O. & Bernmann, M. *Hymenoscyphus fraxineus* vs. *Hymenoscyphus albidus*—a comparative light microscopic study on the causal agent of European ash dieback and related foliicolous, stroma-forming species. *Mycology* 5, 228–290 (2014).
- 6 Desmazières, J.B.H.J. Plantes Cryptogames du Nord de la France. Ed. 1 (Leleux, Lille, France, 1851).
- 7 Kowalski, T., Bilański, P. & Holdenrieder, O. Virulence of Hymenoscyphus albidus and H. fraxineus on Fraxinus excelsior and F. pennsylvanica. PLoS ONE 10, e0141592 (2015).
- 8 Halecker, S. *et al.* Hymenosetin, a 3-decalinoyltetramic acid antibiotic from cultures of the ash dieback pathogen, *Hymenoscyphus pseudoalbidus*. *Phytochemistry* **100**, 86–91 (2014).

- 9 Junker, C., Mandey, F., Pais, A., Ebel, R. & Schulz, B. Hymenoscyphus pseudoalbidus and Hymenoscyphus albidus: viridiol concentration and virulence do not correlate. For. Pathol. 44, 39–44 (2014).
- 10 Citron, C. A., Junker, C., Schulz, B. & Dickschat, J. S. A volatile lactone of *Hymenoscyphus pseudoalbidus*, pathogen of European ash dieback, inhibits host germination. *Angew. Chem. Int. Ed. Engl.* **53**, 4346–4349 (2014).
- 11 Solheim, H. & Hietala, A. M. Spread of Ash Dieback in Norway. Balt. For. 23, 144–149 (2017).
- 12 Nair, M. S. R. & Carey, S. T. Metabolites of Pyrenomycetes XI. Structure of aurocitrin, a new antibacterial pigment from *Hypocrea citrina*. *Tetrahedron Lett.* 35, 3233–3236 (1979).
- 13 Berkaew, P., Soonthornchareonnon, N., Salasawadee, K., Chanthaket, R. & Isaka, M. Aurocitrin and related polyketide metabolites from the wood-decay fungus *Hypocrea* sp. BCC 14122. J. Nat. Prod. 71, 902–904 (2008).
- 14 Nukina, M., Sassa, T., Ikeda, M., Umezawa, T. & Tasaki, H. Pyriculariol, a new phytotoxic metabolite of *Pyricularia oryzae* Cavara. Agric. Biol. Chem. 45, 2161–2162 (1981).
- 15 Teles, H. L. *et al.* Aromatic compounds produced by *Periconia atropurpurea*, an endophytic fungus associated with *Xylopia aromatica. Phytochemistry* **67**, 2686–2690 (2006).
- 16 Miyake, Y., Ito, C., Itoigawa, M. & Osawa, T. Antioxidants produced by *Eurotium herbariorum* of filamentous fungi used for the manufacture of karebushi, dried bonito (Katsuobushi). *Biosci. Biotechnol. Biochem.* **73**, 1323–1327 (2009).
- 17 Surup, F. et al. Deconins A-E: cuparenic and mevalonic or propionic acid conjugates from the basidiomycete *Deconica* sp. 471. J. Nat. Prod. 78, 934–938 (2015).

Supplementary Information accompanies the paper on The Journal of Antibiotics website (http://www.nature.com/ja)